|Day Low/High||7.97 / 8.24|
|52 Wk Low/High||6.08 / 10.38|
Brookdale Senior Living Incorporated (NYSE:BKD) hit a new 52-week high Monday as it changed hands at $23.87 compared with its previous 52-week high of $23.84. Brookdale Senior Living is currently trading at $23.85 with 310,171 shares changing hands as of 11:30 a.m..
Advance Auto upgraded at Oppenheimer from Underperform to Perform. Sales momentum is improving across the industry.
Gregg Greenberg breaks down today's market action with guests Dan Genter, CEO of RNC Genter Capital Management, Ron Laconi, president of the private client group at Chartis and David Peltier, TheStreet's Stocks Under $10 portfolio manager
Traders are bullish on Hartford Financial as shares remain near their 52-week highs, making up ground lost in Friday's selloff.
Merck is upgraded at Credit Suisse to Outperform from Neutral.
Brookdale completes acquisition of 3 senior living centers for $102 million
Movers roundup: Waste Services shares jump on upgrade, GTx falls after delay leads to job cuts
Brookdale Senior Living climbs as Goldman adds to 'Conviction Buy List'
Goldman upgrades 3 REITs, saying there's a bottom within a year and a half and debt costs low
Sunrise says it will sell some US facilities, turn over Fountains properties to settle debts
Supervalu, NetApp, Scientific Learning, Infosys, Acorda are among big market movers Friday
Brookdale to buy 21 senior living communities from Sunrise affiliates for $204 million
Tenet reports a loss on increasing revenue in-line with last week's second quarter preview.
Love and marriage: Political spouses visible, vulnerable to rough campaign world
Earnings roundup: Charter Communications loss narrows, Smart Balance gains market share
Brookdale Senior Living posts smaller 3rd-quarter loss that easily topped Wall Street
The volatile moves in oil, gas, banking and brokerage stocks are creating opportunities for investors, Cramer says.
Guy Adami says that after Biogen Idec, it's the best biotech.
Neurocrine Biosciences and Dov Pharmaceutical tank after disappointing news from the FDA.
Brookdale Senior Living agrees to buy the company for $1.2 billion.
Tuesday's rally helps, but the Comp isn't a buy. Plus, charts of Amgen, Imclone, Andrew and more.
There is no stampede to sell despite some warnings from companies and dicey geopolitics.
The long winter continues for tech as areas like autos and home-improvement retailers begin to bud.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.